Early studies investigated the therapeutic potential of histone deacetylase inhibitors (HDACIs) and demonstrated their ability to increase SMN2 transcription through the modification of chromatin structure in vitro and in vivo SMA models [34,43]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.